Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Trea

– Data from multiple ongoing clinical studies of STK-001 show reductions in convulsive seizure frequency and improvements in cognition and behavior in children and adolescents with Dravet syndrome –– Data support the potential for STK-001 to be the first disease-modifying treatment for Dravet syndrome –– New pharmac...

Related Keywords

United Kingdom ,Cambridge ,Cambridgeshire ,Bedford ,Massachusetts ,United States ,Ireland ,Dublin ,Helen Cross ,Eric Rojas ,Elaine Wirrell ,Im Scott Perry ,Exchange Commission ,International League Against Epilepsy ,Augmentation Of Nuclear Gene Output Is Stoke ,John Justin Neurosciences Center ,Nasdaq ,Cook Children Medical Center ,Stoke Therapeutics Inc ,Company Annual Report On Form ,International Epilepsy Congress ,University College London Institute Of Child Health ,Neurology Residency Training Program At Mayo Clinic ,Augmentation Of Nuclear Gene Output ,Stoke Therapeutics ,Childhood Epilepsy ,Child Health ,Honorary Consultant ,Paediatric Neurology ,Dravet Syndrome ,Senior Vice President ,Clinical Pharmacology ,Digital Poster Presentation ,Ongoing Open Label ,United Kingdom Investigating Safety ,Drug Exposure ,Antisense Oligonucleotide ,Developmental Neuroscience Programme ,International League Against ,Previously Participated ,Genetic Epilepsy Clinic ,Cook Children ,Investigate Cognition ,Pediatric Epilepsy ,Mayo Clinic ,Adolescent Neurology Residency Training Program ,Targeted Augmentation ,Nuclear Gene Output ,Private Securities Litigation Reform Act ,Annual Report ,Investor Contacts ,Investor Relations ,